GlassScriptPhysician profile
Shajla Ajas
NPI 1598241747
$2,444.38
in general payments reported to CMS, 2019-2025
28 companies · $659 in 2025
The $659 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $159 · 2023: $716 · 2024: $910 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,648 · Education: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,648.17 |
| Education | $636.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $509.65 | 2023-2025 | Erleada, Darzalex, Akeega |
| Amgen INC. | $302.56 | 2023-2024 | Lumakras, Blincyto, Kyprolis |
| Astrazeneca Pharmaceuticals LP | $261.74 | 2023-2025 | Enhertu, Lynparza, Calquence |
| Seagen INC. | $243.08 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $168.98 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $141.83 | 2024 | Balversa, Rybrevant |
| Daiichi Sankyo INC. | $138.50 | 2024-2025 | Enhertu, Injectafer |
| Glaxosmithkline, LLC. | $74.26 | 2023-2025 | Zejula, Jemperli, Shingrix |
| Pharmacosmos Therapeutics INC. | $72.79 | 2023-2025 | Monoferric |
| Novartis Pharmaceuticals Corporation | $55.93 | 2024-2025 | |
| Eisai INC. | $52.54 | 2024-2025 | |
| Puma Biotechnology, INC. | $47.74 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $46.60 | 2022-2023 | Pomalyst, Opdivo |
| Merck Sharp & Dohme LLC | $37.25 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $28.63 | 2023-2025 | Reblozyl, Pomalyst |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $25.35 | 2025 | Orserdu |
| Mirati Therapeutics, INC. | $25.00 | 2023 | Krazati |
| Pfizer INC. | $23.18 | 2023 | |
| Aveo Pharmaceuticals, INC. | $22.67 | 2025 | |
| Adaptive Biotechnologies Corporation | $22.45 | 2024 | Clonoseq |
| Genentech USA, INC. | $21.67 | 2024 | Phesgo |
| Astellas Pharma US INC | $19.87 | 2025 | Padcev |
| Genzyme Corporation | $19.61 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.28 | 2025 | |
| Taiho Oncology, INC. | $17.00 | 2025 | |
| Abbvie INC. | $15.50 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $15.37 | 2023 | Imbruvica, Epkinly |
| Emd Serono, INC. | $15.35 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shajla Ajas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.